Mr. Mike Kelly reports

NERVGEN ANNOUNCES APPOINTMENT OF RANDALL KAYE, MD TO CHIEF MEDICAL ADVISOR ROLE

Nervgen Pharma Corp. has appointed Dr. Randall Kaye, MD, to the role of chief medical adviser. Dr. Kaye, a current member of Nervgen's board of directors and chair of the science committee since 2020, brings highly relevant and extensive experience in central nervous system therapeutic development, regulatory strategy and medical affairs to the Nervgen team. The expanded engagement follows the company's announcement of positive top-line results in the chronic cohort of the phase 1b/2a clinical trial evaluating NVG-291 in individuals with cervical spinal cord injury.

"We are very pleased to welcome Dr. Kaye in his expanded capacity as a medical adviser to the company," said Mike Kelly, Nervgen's president and chief executive officer. "In addition to his close history and contributions to the NVG-291 program, he brings extensive industry and CNS development expertise focused on clinical and regulatory strategy. Dr. Kaye has highly relevant experience and is well positioned to assist the team in analyzing the complete chronic cohort data and help chart the next phase of NVG-291's clinical and regulatory pathway, which includes assisting in preparations for our anticipated meeting with the U.S. Food and Drug Administration in the second half of this year."

As a Nervgen board member and science committee chair, Dr. Kaye has served as an adviser to the NVG-291 program since its early clinical development. He previously served as chief medical officer of multiple biopharmaceutical companies, including most recently at Longboard Pharmaceuticals Inc., where he helped guide CNS development programs through a $2.6-billion acquisition by H. Lundbeck A/S. His expertise spans the areas of neurology, psychiatry, immunology and infectious disease, and includes oversight of clinical operations, regulatory affairs and medical strategy. Dr. Kaye earned his MD, MPH and BS degrees from George Washington University, and completed a research fellowship at Harvard medical school.

About Nervgen Pharma Corp.

Nervgen is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a phase 1b/2a clinical trial in spinal cord injury. Top-line data from the chronic cohort (one to 10 years postinjury) of this trial showed that NVG-291 met its primary end point and demonstrated promising changes in a secondary end point assessing hand function. Enrolment in the subacute cohort (20 to 90 days postinjury) of the trial continues, and more information about participation in the subacute study is available on-line. In addition, the company has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury.

We seek Safe Harbor.